Ariad Pharmaceuticals Incorporated - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Ariad Pharmaceuticals Incorporated Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Ariad Pharmaceuticals Incorporated. The Group's principal activities are the discovery and development of medicines that treat cancer by regulating cell signaling with small molecules. The Group's lead product candidate, AP23573, is in multiple Phase 1 and Phase 2 clinical trials and is used for the treatment of solid tumors and hematologic cancers. In the Group's bone-targeted mTOR inhibitor program, it is developing a novel and potent follow-on product candidate analogous to AP23573, which treats bone cancers and block the spread of bone sarcomas. In the Group's oncogenic kinase inhibitor program, it is developing potent inhibitors of enzymes involved in the growth, proliferation and spread of cancer. The Group operates in the United States.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report